Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
MXCT vs DCTH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
DCTH Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)
DCTH Overall Winner
6-Pillar Tally: MXCT 0 – 6 DCTH
Matrix Metrics: MXCT 2 – 8 DCTH
As of Nov 20, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas DCTH carries 35.2/100 (SELL) at $18.79 (69.0x Forward P/E, 5.2% operating margin).
- Composite vs. Pillar Nuance: While MXCT currently prints a higher short-term Unified Composite Score (41.7/100 SELL vs. DCTH 35.2/100 SELL), DCTH captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -85.5% operating margin) and revenue trajectory (+70.7% vs. +48.7% YoY).
- Defensive Composite Rating Caution: Although DCTH compares more favorably head-to-head, both MXCT (41.7/100 SELL) and DCTH (35.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About MXCT vs DCTH
MXCT
MaxCyte, Inc. Common Stock
$1.37
+7.03% 1D
Market Cap
$132.2M
TTM Revenue
$34M
Forward P/E
N/M
Beta / 30D Vol
1.19β · 96% Vol
Unified Composite Score
41.7
SELL
Tech 46.0
Fund 52.0
Flow 62.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
DCTH
Head-to-Head Winner
Delcath Systems Inc
$18.79
-2.34% 1D
Market Cap
$669.3M
TTM Revenue
$110M
Forward P/E
69.0x
Beta / 30D Vol
1.57β · 130% Vol
Unified Composite Score
35.2
SELL
Tech 50.0
Fund 36.0
Flow 70.0
Mom 44.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (MXCT 0 – 6 DCTH)
1. Valuation Multiples
DCTH
Forward P/E
N/M
69.0x
Trailing P/E
N/M
120.2x
PEG Ratio
N/M
1.60x
EV / Revenue
3.9x
5.6x
2. Growth & Scale
DCTH
Revenue Growth (YoY)
+48.7%
+70.7%
Earnings Growth (YoY)
+0.0%
+750.0%
TTM Revenue (USD)
$34M
$110M
Market Cap
$132.2M
$669.3M
3. Profitability & Quality
DCTH
Gross Margin
81.0%
87.6%
Operating Margin
-85.5%
5.2%
Net Profit Margin
-81.4%
6.0%
Return on Equity (ROE)
-16.9%
5.4%
4. Balance Sheet & Cash Flow
DCTH
Cash Generation (TTM)
-$24M
$20M
Cash Flow Margin
-69.2%
18.3%
Net Cash / Leverage
$2.2M Net Debt (0.11x D/E)
$53M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
DCTH
Options Structure Phase
UNCLASSIFIED
CONSOLIDATION
Current IV / %ile
N/A (N/A)
64.8% (26th %ile)
Put/Call OI Skew
N/A
0.22x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markup
DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat
DCTH
OpEx & R&D Intensity
N/A
82.4% of Rev ($91M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: MXCT (2) vs DCTH (8)| Institutional Metric | MXCT | DCTH | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $132.2M | $669.3M | DCTH | |
| Trailing P/E Ratio | N/M | 120.2x | DCTH | |
| Forward P/E Ratio | N/M | 69.0x | DCTH | |
| Revenue Growth (YoY) | +48.7% | +70.7% | DCTH | |
| Operating Margin (TTM) | -85.5% | 5.2% | DCTH | |
| Net Profit Margin | -81.4% | 6.0% | DCTH | |
| Return on Equity (ROE) | -16.9% | 5.4% | DCTH | |
| 52-Week Range Position | 63% ($1–$2) | 74% ($8–$23) | DCTH | |
| Beta / 30D Volatility | 1.19β · 96% Vol | 1.57β · 130% Vol | MXCT | |
| Unified Institutional Score | 41.7 / 100 (SELL) | 35.2 / 100 (SELL) | MXCT | |
| Trailing 12M Revenue (USD) | $34M | $110M | Scale | |
| Gross Profit Margin (TTM) | 81.0% | 87.6% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 3.9x EV/Rev | 1.60x PEG · 5.6x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$24M ($2.2M Net Debt (0.11x D/E)) | $20M ($53M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
DCTH +31.59 pp
3M Horizon
DCTH +13.62 pp
6M Horizon
DCTH +38.78 pp
1Y Horizon
DCTH +140.21 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MXCT Revenue | DCTH Revenue | MXCT Op. Margin | DCTH Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2015 | N/A | $0M | N/A | -870.6% | DCTH |
| FY2019 | $10M | N/A | -93.7% | N/A | MXCT |
| FY2020 | $20M | N/A | -71.6% | N/A | MXCT |
| FY2021 | $20M | $0M | -84.3% | -690.0% | MXCT |
| FY2022 | $30M | $0M | -95.2% | -1245.1% | MXCT |
| FY2023 | $20M | $0M | -247.7% | -1849.0% | MXCT |
| FY2024 | $20M | $40M | -230.5% | -33.4% | DCTH |
| FY2025 | $20M | $90M | -247.6% | 0.8% | DCTH |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
MXCT
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact MXCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
DCTH
CONSOLIDATION
Current IV
64.8%
IV Percentile
26th %ile
Put/Call OI Skew
0.22x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
MXCT Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
DCTH Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
82.4% of Rev ($91M)
90D Engineering Disclosures
0 Published
Investor FAQ MXCT vs DCTH Key Questions & Quantitative Answers
As of Nov 20, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas DCTH carries 35.2/100 (SELL) at $18.79 (69.0x Forward P/E, 5.2% operating margin). Composite vs. Pillar Nuance: While MXCT currently prints a higher short-term Unified Composite Score (41.7/100 SELL vs. DCTH 35.2/100 SELL), DCTH captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -85.5% operating margin) and revenue trajectory (+70.7% vs. +48.7% YoY). Defensive Composite Rating Caution: Although DCTH compares more favorably head-to-head, both MXCT (41.7/100 SELL) and DCTH (35.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
DCTH leads the Growth & Scale pillar: MXCT posts +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin), compared with DCTH at +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin). Across the 8-period historical trajectory (FY2015 to FY2025), MXCT cumulative revenue shifted +100.0% while DCTH shifted +125.0%. In operating R&D and SG&A reinvestment, MXCT deploys N/A (0 90-day corporate R&D disclosures) versus 82.4% of Rev ($91M) (0 disclosures) for DCTH.
DCTH screens cheaper on headline valuation multiples. MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin), whereas DCTH trades at 69.0x Forward P/E, 120.2x Trailing P/E, 1.60x PEG, and 5.6x EV/Revenue (18.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MXCT (-16.9% ROE) versus DCTH (5.4% ROE) capital efficiency.
In options market volatility and institutional positioning, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk). By comparison, DCTH carries 64.8% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.22x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.57β · 130% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
DCTH vs MXCT · Reverse Pair
MXCT vs CTKB
· Sector Peer
MXCT vs SGHT
· Sector Peer
MXCT vs TMCI
· Sector Peer
DCTH vs CRMD
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma